Icahn School of Medicine at Mount Sinai psychedelic research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
Icahn School of Medicine at Mount Sinai is listed with 19 registered studies counted here, in New York, United States. By compound: 2 psilocybin, 2 MDMA and 15 ketamine. By registry status: 6 recruiting, 1 active, not recruiting, 8 completed, 2 terminated and 2 withdrawn. By phase: 3 phase 1, 11 phase 2, 3 phase 4 and 2 not applicable. Reported start years run from 2007 (earliest) to 2026 (latest).
Institution name, city and country are copied from the research site linked to each registry record. A study counts once per institution, and a study tagged with more than one compound is counted under each compound.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 19 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 2 |
| MDMA | 2 |
| Ketamine | 15 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 6 | 32% |
| Active, not recruiting | 1 | 5% |
| Completed | 8 | 42% |
| Terminated | 2 | 11% |
| Withdrawn | 2 | 11% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 3 | 16% |
| Phase 2 | 11 | 58% |
| Phase 4 | 3 | 16% |
| Not applicable | 2 | 11% |
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| MDMA Assisted Therapy for BN | NCT07542145 | Recruiting | Phase 1 | 2026-05-01 | MDMA |
| MDMA-Assisted Therapy for Mental Healthcare Providers | NCT07102576 | Recruiting | Phase 1 | 2026-01-01 | MDMA |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | NCT06899165 | Recruiting | Phase 2 | 2025-08-28 | Psilocybin |
| Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder | NCT06592833 | Recruiting | Phase 2 | 2025-02-25 | Psilocybin |
| Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression | NCT06559826 | Recruiting | Phase 2 | 2025-01-10 | Ketamine |
| Single-dose Ketamine Treatment to Improve Depression in Mild Cognitive Impairment | NCT06069843 | Active, not recruiting | Phase 2 | 2024-11-01 | Ketamine |
| Neural Circuit Effects of Ketamine in Depression | NCT06213324 | Recruiting | Phase 4 | 2024-01-31 | Ketamine |
| Intramuscular Ketamine for Suicidal Ideation | NCT05105061 | Withdrawn | Phase 2 | 2022-02-01 | Ketamine |
| Effect of Ketamine on Laboratory-induced Stress in Healthy Subjects | NCT04173962 | Completed | Phase 2 | 2019-08-08 | Ketamine |
| Ketamine and Nitroprusside for Depression | NCT03102736 | Completed | Phase 2 | 2017-02-14 | Ketamine |
| Ketamine as a Treatment for Post-Traumatic Stress Disorder (PTSD) | NCT02397889 | Completed | Phase 2 | 2015-05-18 | Ketamine |
| To Test the Potential Efficacy of Repeated Intranasal Administration of Ketamine as a Treatment for PTSD | NCT02398136 | Withdrawn | Phase 2 | 2014-12-01 | Ketamine |
| Ketamine Plus Lithium in Treatment-Resistant Depression | NCT01880593 | Completed | Phase 2 | 2013-07-01 | Ketamine |
| Ketamine For Suicidal Ideation | NCT01507181 | Completed | Phase 4 | 2012-01-01 | Ketamine |
| Intranasal Ketamine in Treatment-Resistant Depression | NCT01304147 | Completed | Not applicable | 2011-10-01 | Ketamine |
| Use of Ketamine to Enhance Electroconvulsive Therapy (ECT) in Depression | NCT01309581 | Terminated | Not applicable | 2010-04-01 | Ketamine |
| Treatment Study of Bipolar Depression | NCT00947791 | Terminated | Phase 4 | 2009-07-01 | Ketamine |
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) | NCT00749203 | Completed | Phase 2 | 2009-01-01 | Ketamine |
| Continuation Ketamine in Major Depression | NCT00548964 | Completed | Phase 1 | 2007-10-01 | Ketamine |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine